TransMedics Group (TMDX) Misses Q3 EPS by 17c, Updates Guidance

Go back to TransMedics Group (TMDX) Misses Q3 EPS by 17c, Updates Guidance

TransMedics Reports Third Quarter 2024 Financial Results

October 28, 2024 4:05 PM EDT

ANDOVER, Mass., Oct. 28, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2024.

... More